Ap­pil­i's Covid-19 oral an­tivi­ral fails PhI­II tri­al; On­col­o­gy biotech Ankyra rais­es $45M in Se­ries B

Ap­pili Ther­a­peu­tics’s in­ves­ti­ga­tion­al oral an­tivi­ral Avi­gan/Reeqonus failed in a Phase III tri­al, the biotech said in a state­ment this morn­ing.

The No­va Sco­tia biotech’s PRESECO …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER